Latest News from JointMedica

Earlier this month, the JointMedica team participated in our first FDA Orthopedic Vendor Day at the FDA headquarters in Silver Spring, Maryland. The day was both busy and highly productive, with our team engaging directly with FDA engineers, reviewers, and leadership through a series of meaningful discussions and hands-on demonstrations. A key highlight was the opportunity to further showcase our PHR® and THA systems, and to share the progress on our IDE study directly wi

A defining achievement has been reached in the evolution of hip preservation technology, the Polymotion® Hip Resurfacing (PHR®) IDE study has officially achieved full enrolment. On Friday, April 3rd, Dr. William Macaulay at NYU Langone performed the final procedure, bringing recruitment to a close and highlighting the growing interest in bone-conserving treatment options for young, active patients. The study began on January 22, 2025, with the first procedures performed by Mr

Earlier this week, Dr Craig Della Valle performed his latest Polymotion Hip Resurfacing procedure at Rush University Medical Center in Chicago. Dr. Della Valle, a highly respected orthopaedic surgeon and Professor of Orthopaedic Surgery at Rush University Medical Center, has performed more than 11,000 hip and knee replacements and continues to play a leading role in advancing hip resurfacing techniques and research. The Polymotion® Hip Resurfacing System, developed by Joint

The Polymotion® Hip Resurfacing (PHR®) IDE study has now reached 95% enrolment , marking an important milestone as the study moves confidently toward full recruitment. The past couple of months have represented a strong and productive start to 2026, with continued momentum across participating clinical sites. This achievement reflects sustained engagement from both surgeons and patients who are seeking modern, bone-conserving alternatives to total hip replacement. The Polymot

A recent systematic review and Meta-Analysis published in JBJS Reviews compared hip resurfacing arthroplasty (HRA) with large-diameter head metal-on-metal total hip arthroplasty (LDH-THA) across 21 studies. Key Findings Lower revision rates with HRA (7.8%) compared with LDH-THA (16%). Significantly lower cobalt and chromium ion levels in patients undergoing hip resurfacing. Functional and activity scores tended to favour HRA, although differences were not consistently stat

Today marks the one-year anniversary of the first Polymotion® Hip Resurfacing implant surgery conducted as part of the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study, a pivotal milestone in the development of this next-generation hip preservation technology. The first IDE study procedure was completed on January 22, 2025, by Mr Ronan Treacy and Dr William Peckett at King Edward VII Memorial Hospital (Bermuda). This inaugural case marked t

The Polymotion® Hip Resurfacing (PHR®) IDE study is closing out 2025 on a high note, having reached 85% enrolment. This milestone represents substantial progress toward study completion and reflects a successful year of steady recruitment across participating sites. As enrolment advances toward its final phase, the study continues to demonstrate strong engagement from both surgeons and patients who are seeking modern, bone-conserving alternatives to total hip replacement. The

Last month marks three years since Dr Jim MacKenzie performed the world’s first Polymotion® Hip Resurfacing (PHR®) procedure in Calgary on 15th November 2022, a milestone in orthopaedic surgery. The procedure, introduced during an event celebrating Dr MacKenzie’s 20 years of experience in hip resurfacing, showcased the latest metal-on-polyethylene implant design from JointMedica. Designed for active patients seeking bone-conserving alternatives to traditional hip arthroplas